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Purpose: Accelerated partial breast irradiation (A-PBI) in Korean women has been
considered impracticable, owing to small breast volume and lack of high-precision
radiotherapy experience. We present the first experience of stereotactic-PBI (S-PBI) with
CyberKnife M6 to investigate feasibility of use and early toxicities in Korean women with
early breast cancers.
Materials and Methods: A total of 104 breasts receiving S-PBI at our
institution between September 2017 and October 2018 were reviewed. Patients were
selected based on the American Society for Radiation Oncology (ASTRO), American
Brachytherapy Society, American Society of Breast Surgeons, and Groupe Européen
de Curiethérapie-European Society for Therapeutic Radiology and Oncology guidelines.
A dose of 30Gy in 5 fractions (NCT01162200) was used. Gold fiducials were routinely
inserted near the tumor bed for tracking. Constraints regarding organs-at-risk followed
the NSABP-B39/RTOG 0413 protocol.
Results: Median follow-up was for 13 months. Patients were categorized as “suitable”
(71.2%) or “cautionary” (28.8%) according to 2017 the ASTRO guidelines. No tracking
failure of inserted gold fiducials occurred. Median planning target volume (PTV) and
PTV-to-whole breast volume ratio was 73.6mL (interquartile range, 58.8–103.9mL) and
17.0% (13.3–19.1%), respectively. Median PTV V95%, PTV Dmax, and ipsilateral breast
V50% were 97.8% (96.2–98.8%), 105.3% (104.2–106.4%), and 35.5% (28.3–39.8%),
respectively. No immediate post-S-PBI toxicity ≥ grade 2 was reported, except grade 2
induration in three breasts. All patients remain disease-free to date.
Conclusion: The first use of S-PBI in Korean women was feasible and safe for selected
early breast cancer. Based on these results, we have initiated a prospective study
(NCT03568981) to test S-PBI in whole-breast irradiation for low-risk early breast cancer.
Keywords: stereotactic partial breast irradiation, accelerated partial breast irradiation, breast cancer, Korean,
feasibility studies, dosimetric outcomes, early toxicity
Lee et al. Stereotactic Partial Breast Irradiation
INTRODUCTION
Accelerated partial breast irradiation (A-PBI) has emerged as an
alternative to whole- breast irradiation (WBI). Previous studies
in patients with low-risk early-stage breast cancer show that
rates of local recurrence after A-PBI are extremely low, and
most cases are limited to the vicinity of the original tumor bed
(1, 2). Several prospective randomized trials demonstrated that
A-PBI is associated with a non-inferior ipsilateral breast tumor
recurrence (IBTR) rate, excellent cosmesis, and low treatment-
related toxicity compared to WBI; however, there are some
variabilities in outcomes owing to use of different radiation
techniques and patient selection criteria (3–6). However, while A-
PBI has been widely adopted worldwide for low-risk early breast
cancer patients, A-PBI adoption remains limited in South Korea.
The “Patterns of practice” study revealed that the use of A-PBI is
far from widespread in South Korea (7).
With advancements in high-precision radiotherapy
techniques, stereotactic body radiation therapy has become
an emerging option for early breast cancer, in the form of
stereotactic A-PBI (S-PBI). Several Western institutions have
shown that S-PBI is a safe and feasible treatment in patients with
early breast cancer who meet strict criteria (8–10).
Given this background, we have implemented A-PBI in
Korean women, and report here our first experience in South
Korea of using S-PBI for low-risk early breast cancer. Our aim
was to investigate the feasibility and early treatment toxicity
profile of S-PBI in Korean women.
MATERIALS AND METHODS
Patient Selection
We reviewed patients treated with S-PBI using CyberKnife M6
(Accuray Incorporated, Sunnyvale, CA, USA) at our institution
between September 2017 and October 2018. Patients referred for
radiotherapy after breast-conserving surgery for breast cancer
were screened by radiation oncologists for suitability for S-
PBI, based on consensus guidelines of the American Society for
Radiation Oncology (ASTRO), American Brachytherapy Society
(ABS), American Society of Breast Surgeons (ASBS), and Groupe
Européen de Curiethérapie-European Society for Therapeutic
Radiology and Oncology (GEC-ESTRO) (11–14). Patients with
invasive lobular carcinoma were eligible for S-PBI, as ASBS and
ABS guidelines accept all invasive subtypes, whereas ASTRO
and GEC-ESTRO guidelines accept invasive lobular carcinoma
as “cautionary” and “intermediate risk,” respectively. In our
institution, invasive lobular carcinoma with no multiplicity
found in preoperative image and surgical pathology, and
satisfying other criteria in the guidelines were eligible for S-PBI.
Low risk breast cancer patients in this study were defined as
patients satisfying the criteria of all of the above guidelines. These
low risk patients were preferentially selected for S-PBI. Physicians
explained expected benefits and risks of S-PBI in contrast to
conventional WBI to these selected patients, and S-PBI was given
to those only who agreed the treatment. Updates to guidelines
during the course of the study were applied immediately (15,
16). Ultimately, patients categorized as “suitable” as well as
“cautionary” according to ASTRO guidelines were included in
the study.
Patients who experienced surgical complications, had positive
resection margins, were younger than 45 years, or had
multicentric tumors were ineligible for S-PBI. Only patients
who had a follow-up period of longer than 6 months were
included in this study. All patients diagnosed with breast cancer
were evaluated preoperatively using breast magnetic resonance
imaging (MRI), ultrasonography, and mammography.
Fiducial Insertion and Simulation
S-PBI performed with CyberKnife M6 tracked gold fiducials
inserted near the tumor bed as fiducial markers. At
commencement of the study in September 2017, the gold
fiducials were routinely inserted, with three gold fiducials
inserted into patients’ breasts at a 1 cm margin from the
postoperative tumor cavity under ultrasonographic guidance.
Upon insertion, the fiducials were placed in a non-coplanar
position with respect to the radiographic orthogonal images of
the CyberKnife M6, and the greatest possible extent of angular
separation was aimed for. Mammography was performed
immediately after insertion to confirm the presence of the
gold fiducials, and simulation computed tomography (CT)
was carried out at least 1 week later to minimize the effect of
fiducial migration (17). Non-contrast 1mm cut CT images
were obtained, with the surgical scar marked by a radiopaque
angiocatheter. Vac-Lok (CIVCO Radiotherapy, Coralville, IA,
USA) devices were used to immobilize patients in the supine
position with arms placed overhead (Figure S1).
Treatment Planning
Ct images were imported intoMIM software (MIM Software Inc.,
Cleveland, OH, USA) for target delineation. The surgical tumor
cavity was identified based on pre- and postoperative images,
surgical clips, and the incisional scar. The clinical target volume
(CTV) was defined as a uniform 1 cm margin expansion from
the tumor cavity, excluding the skin and chest wall. A margin
of at least 5mm from the breast skin surface was required.
Chest wall structures, such as the pectoralis muscle or ribs, were
excluded from the CTV. We defined the planning target volume
(PTV) as equal to the CTV, using a robotic stereotactic tracking
system capable of real-time respiratory tracking. The ipsilateral
breast, contralateral breast, skin, chest wall, both lungs, heart,
left anterior descending coronary artery, esophagus, thyroid, and
spinal cord were delineated as organs-at-risk. The contoured
PTV and ipsilateral whole-breast volume were measured using
MIM software. The PTV-to-whole-breast ratio (PTV/WB) was
calculated for each breast. An example of target delineation for
S-PBI is shown in Figure 1.
The prescribed dose was 30Gy in 5 fractions, identical to that
used in work reported by the University of Texas Southwestern
(UTSW), which proved safe and feasible in their phase I study
(NCT01162200) (10). Following this regimen, radiotherapy was
delivered every other day. The S-PBI was planned such that
the PTV receiving 95% of the prescribed dose (V95%) would
be over 95% of the total PTV, and the maximum point dose
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FIGURE 1 | Example of axial cut image showing target delineation for stereotactic accelerated partial breast irradiation in a sample patient. PTV, planning target
volume.
(Dmax) allowed for the PTV was <107%. Constraints to organs-
at-risk mostly followed those of the NSABP B-39/RTOG 0413
protocol: ipsilateral breast V50% < 60%, contralateral breast Dmax
< 1Gy, ipsilateral lung V30% < 15%, heart (right-sided lesions)
V5% < 5%, and heart (left-sided lesions) V5% < 40%. Doses to
the contralateral lung, skin, chest wall, and thyroid were also
considered according to the NSABP B-39/RTOG 0413 protocol.
Treatment and Follow-Up
Robotic stereotactic radiotherapy using the CyberKnife M6 with
fiducial tracking was used in all patients. Before every treatment,
orthogonal X-ray images (from 45 and 135◦ angles with respect
to the surface) were acquired after patient setup to visualize and
align the fiducials with those in the original orthogonal X-ray
images. If only two fiducials were detectable, treatment required
authorization from a radiation oncologist.
Patients were interviewed and examined by the treating
physician during the course of therapy, followed by routine
visits every 6–12 months after S-PBI. Routine surveillance
consisted of medical interviews, breast examinations, and
mammography, in addition to optional breast ultrasonography
and MRI. Toxicity assessment was performed using the Harvard
scale, and mainly included breast skin change and induration
assessments. In addition, skin thickness was measured by
assessing ultrasound images obtained before surgery and 6–12
months after radiotherapy (if available). Both the skin above the
tumor bed and the skin of the opposite quadrant of the ipsilateral
breast (at least 5 cm away from the tumor bed) were measured at
each time point.
For this study, we selected a cohort of 237 breasts that received
WBI during the same period that the S-PBI was undertaken,
for comparison of patient characteristics, toxicity, and skin
thickness. All these breasts exhibited pathologically Tis or T1,
node-negative breast cancers that received WBI of 40.05Gy in
15 fractions, combined with a simultaneously integrated boost of
48Gy in 15 fractions to the tumor bed by intensity-modulated
radiation therapy (IMRT) after breast-conserving surgery.
Ethical Statement
The hospital’s institutional review board approved the
retrospective review of S-PBI patients for this study (4-
2019-0054). The necessity of written informed consent was
waived due to the retrospective nature of the study, and the




Between September 2017 and October 2018, 911 patients (922
breasts) were referred for radiotherapy after undergoing breast-
conserving surgery. After screening, 103 patients (104 breasts;
11.3% of total referred breasts) received S-PBI. The median
follow-up was 13 months (range, 6–21 months). The patient
characteristics are summarized in Table 1. Among the total of
103 patients, the median age was 60 years (range, 46–85 years).
Of the total of 104 breasts, 75 (72.1%) had invasive ductal
carcinoma, with a median tumor size of 1.0 cm (range, 0.1–
2.5 cm). Three patients had metastatic lymph nodes (1–2 sentinel
lymph node metastases with no perinodal extension). The tumor
grade was 1 or 2 in 97 breasts (93.3%). None of the tumors had
lymphovascular invasion, and all had clear resection margins.
All tumors except 1 were estrogen receptor-positive. The breasts
were categorized as “suitable” (71.2%) or “cautionary” (28.8%)
according to the updated 2017 ASTRO guidelines. The most
common reason for classification as “cautionary” was extensive
intraductal carcinoma of <3 cm (18 breasts). Compared to the
pathologically Tis or T1, node negative WBI cohort, the S-PBI
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TABLE 1 | Patient characteristics (per breast).
Characteristic N %











Close or Positive 0 0.0
Grade
Grade 1 53 51.0
Grade 2 44 42.3














DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; N stage, nodal stage; RM,
resection margin; LVI, lymphovascular invasion; EIC, extensive intraductal carcinoma; ER,
estrogen receptor; ASTRO, American Society for Radiation Oncology.
patients had younger age (p < 0.01), lower tumor grade (p
< 0.01), less lymphovascular invasion (p < 0.01), and more
estrogen receptor positivity (p < 0.01) (Table S1). The WBI
cohort had trend toward more positive resection margin, larger
tumor size, and more extensive intraductal component, although
not statistically significant.
Technical Feasibility of S-PBI
All 104 breasts had real-time tracking with inserted gold fiducials.
All three inserted fiducials were trackable in 83 breasts (75.5%),
and two of the three were trackable in 27 breasts (24.5%). There
was no treatment interruption, reinsertion of fiducials, or re-
simulation owing to tracking failure. The median treatment time
was 33min (range, 25–45min) (Table 2).
Dosimetric Outcomes
The median whole-breast volume was 481.1mL [interquartile
range (IQR), 375.1–646.4mL], while the median PTV was
73.6mL (IQR, 58.8–103.9mL). The median PTV/WB was
TABLE 2 | Treatment characteristics.
Characteristic N %
Number of tracked gold fiducials (among inserted)
3 fiducials 81 77.9
2 fiducials 23 22.1
Treatment time (min; median, range) 33 (25-45)
TABLE 3 | Dosimetric outcomes of stereotactic partial breast irradiation.
Dosimetric parameters Median (interquartile range)
PTV V95% 97.8% (96.2–98.8%)
PTV Dmax 105.3% (104.2–106.4%)
Ipsilateral breast V50% 35.5% (28.3–39.8%)
Contralateral breast Dmax 0.8Gy (0.6–1.1Gy)
Ipsilateral lung V20Gy 0.1% (0.0–0.3%)
Ipsilateral lung V10Gy 2.2% (1.5–3.0%)
Contralateral lung V1.5Gy 0.0% (0.0–0.0%)
Heart mean dose (left-sided lesions) 0.7Gy (0.5–1.2Gy)
Heart mean dose (right-sided lesions) 0.4Gy (0.3–0.5Gy)
Skin Dmax 26.6Gy (25.5–28.0Gy)
Chest wall Dmax 29.8Gy (29.2–30.5Gy)
Vx%, percentage of volume receiving X% of the prescribed dose; VxGy , percentage of
volume receiving X Gy; Dmax , maximum point dose.
17.0% (IQR, 13.3–19.1%). The dosimetric parameters for S-
PBI in this study are shown in Table 3, while the PTV
and PTV/WB in this study are compared to those found in
other similar S-PBI studies in Table S2. The median PTV
V95% was 97.8% (IQR, 96.2–98.8%), and PTV Dmax was
105.3% (IQR, 104.2–106.4%). The median ipsilateral breast
V50%, ipsilateral lung V10Gy, and contralateral lung V1.5Gy
were 35.5% (IQR, 28.3–39.8%), 2.2% (IQR, 1.5–3.0%), and
0.0% (IQR, 0.0–0.0%), respectively. The median skin and
chest wall Dmax were 26.6Gy (IQR, 25.5–28.0Gy) and 29.8Gy
(IQR, 29.2–30.5Gy), respectively. The mean dose for the
heart was a median of 0.7Gy (IQR, 0.5–1.2Gy) and 0.4Gy
(IQR, 0.3–0.5Gy), for left- and right-sided lesions, respectively.
Figure 2 shows an example of an isodose line and dose-
volume histogram of an S-PBI plan that successfully satisfied all
dosimetric goals.
Physician-Rated Early Toxicity and Change
in Breast Skin Thickness
After a median follow-up of 13 months, no IBTR, regional
recurrence, or distant metastasis was detected in any of the
patients. Figure 3 shows the toxicity data at the end of each
follow-up period. Immediately after S-PBI, 87 breasts (83.7%)
had no breast skin color change, and 66 (63.4%) had no
palpable induration. No grade 2 or higher breast color change
was reported, and grade 2 induration was observed in 3
breasts, which had persisted threesince immediately after the
completion of surgery. After 6 months of follow-up, grade 1
color change and grade 1 palpable induration were noted in
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FIGURE 2 | Example of (A) an isodose line (upper: axial; lower: sagittal) and (B) dose-volume histogram of a stereotactic accelerated partial breast irradiation plan that
satisfies all dosimetric goals. PTV, planning target volume.
FIGURE 3 | Early toxicity outcomes: (A) skin change and (B) breast induration after S-PBI. S-PBI, stereotactic partial breast irradiation; m, months.
one and four breasts, respectively. Among the 56 breasts where
follow-up of 1 year was reached, none showed color change
and only one showed grade 1 induration. The WBI cohort
showed similar results after 1 year of follow-up (135 breasts),
as all except two breasts with grade 1 color change showed
no color change, and two breasts had grade 1 induration.
In terms of other treatment-related toxicities after S-PBI, one
breast had grade 1 breast edema, and one breast had grade
2 breast cellulitis which was successfully managed with oral
antibiotics. No rib fracture or radiation pneumonitis was noted
after S-PBI.
The change in skin thickness from before surgery to 6–
12 months after radiotherapy was compared in the skin above
the tumor bed and the skin of the opposite quadrant of the
tumor bed (Figure 4). In S-PBI breasts, the median increase
in skin thickness above the tumor bed was 800µm (range,
−600 to +3,200µm), while skin of the opposite quadrant of
the tumor bed in the ipsilateral breast increased by a median of
100µm (range,−600 to+1,100µm). InWBI breasts, the median
increase in skin thickness above the tumor bed was 1,000µm
(range, −200 to +5,200µm), while in the opposite quadrant of
the tumor bed in the ipsilateral breast it increased by a median of
400µm (range, −300 to +3,300µm). Changes in skin thickness
of the opposite quadrant were significantly smaller in the S-PBI
group compared to the WBI group (p < 0.01).
DISCUSSION
Our first experience of S-PBI revealed that it is a feasible and
safe treatment in low-risk early breast cancer in Korean women.
The high-precision radiotherapy technique showed excellent
fiducial tracking abilities, with excellent dosimetric outcomes and
minimal early toxicity, despite the relatively small breast volumes.
To our knowledge, this is the first experience of S-PBI use in
Korean women.
Over the last three decades, prospective trials using various
techniques have demonstrated that A-PBI is non-inferior to WBI
(3–6). However, only 4.7% of total radiation oncology facilities
in South Korea use A-PBI (7). This could be due to several
reasons. First, patient selection is limited, owing to the younger
age distribution of breast cancer in South Korea compared to
the Western hemisphere (18). In addition, even though many
radiation oncologists have sufficient clinical experience in high-
precision radiotherapy, they usually feel that it is unnecessary
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FIGURE 4 | Changes in skin thickness after surgery followed by stereotactic partial breast irradiation (S-PBI) or whole-breast irradiation (WBI). Changes in skin
thickness are defined as breast skin thickness before surgery, subtracted from breast skin thickness at 1 year after radiation. Values are presented in micrometers
(range).
to apply such techniques because of the relatively small breast
volumes and favorable clinical outcomes with conventional
techniques. Lastly, but most practically, the Korean National
Health Insurance (KNHI) program’s reimbursement system,
based on fraction number, has been a major obstacle to use
of A-PBI.
Radical advances in IMRT and image guidance have provided
a potential breakthrough for A-PBI, as shown in an Italian
prospective trial (19). S-PBI, a further developed form of high-
precision IMRT, has the potential to circumvent the limitations
in Korean women. While A-PBI using conventional IMRT may
carry risks owing to respiratory motion uncertainty, the novel
high-precision technique of S-PBI addresses this with real-
time motion tracking via fiducial markers, allowing minimal
PTV margin expansion. We believe that S-PBI could provide a
breakthrough for A-PBI in South Korea.
Our S-PBI was performed after careful patient selection.
We considered all available A-PBI guidelines for selecting the
patients. Only 6.2% of total breasts referred for radiotherapy were
selected for S-PBI, and none were categorized as “unsuitable”
according to the ASTRO guidelines. The results of strict patient
selection are well described in Table S1, showing S-PBI patients
bearing much more favorable clinicopathologic features. We
were especially cautious when selecting patients aged 45–50
years, the gray zone among different guidelines (11–16). In this
age group, only those without any relative contraindications were
selected. As a result, despite the young age at which breast cancer
frequently occurs in South Korea, as mentioned previously (18),
we successfully managed to select an optimal group of Korean
women for S-PBI.
We have also shown the technical feasibility of S-PBI in low-
risk patients with early breast cancer. S-PBI was highly successful
in terms of fiducial utilization, as no tracking failure occurred
with routine gold fiducial insertion. All patients deemed eligible
for A-PBI successfully underwent the procedure after fiducial
insertion. The safety and efficacy of gold fiducial insertion for
A-PBI has been well established by the UTSW, whose methods
we followed (17). Moreover, the treatment time per fraction
remained reasonable, compared to the UTSW S-PBI study (10).
Each S-PBI treatment may be relatively longer than that for
WBI, but the substantially shortened treatment total fraction
ultimately saves both time and costs. Our first attempt at S-PBI
in South Korea successfully proved that it is technically feasible
in Korean women.
The dosimetric analyses in this study showed that S-PBI
with minimal PTV expansion resulted in excellent dosimetric
parameters in Korean women. During our initial S-PBI setup, we
intended to set dose-volume constraints and define PTV based
on the NSABP B-39/RTOG 0413 protocol, which establishes PTV
as a uniform 1 cm expansion of CTV. However, we believed that
modification of the definition of PTV was necessary, considering
poor dosimetric outcomes in the ipsilateral breast in the Korean
Radiation Therapy Oncology Group (KROG) 0804 study (20).
Based on the high precision of S-PBI with successful fiducial
tracking, and the preference of our surgeons for cavity shave
margins over inked margins, we chose a much smaller PTV
definition than that of the NSABP B-39/RTOG 0413 protocol.
As a result, not only were the ipsilateral breast dosimetric
goals successfully satisfied in all breasts in our study, but the
median ipsilateral breast V50% in our study was 35.8%, much
lower than that of the KROG study (20). Compared to the
Western A-PBI reports (Table S2), the ipsilateral breast V50%
in our patients was as low as those in Western S-PBI studies
(9, 21, 22), and dramatically lower than in A-PBI studies
using three-dimensional conformal radiation therapy (3D-CRT),
ranging from 42 to 49% (23–26). This could be explained by
the substantial PTV margin expansion mandated by respiratory
and setup uncertainties in 3D-CRT. Likewise, our delicate S-PBI
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planning achieved consistent dosimetric profiles compared to
those observed in Western S-PBI studies in other organs-at-
risk, without compromising PTV coverage or creating PTV hot
spots (9, 21, 22). These results demonstrated that S-PBI could
overcome the disadvantage of relatively small breast volumes in
Korean women.
Early toxicities after S-PBI were minimal in our study.
Although a few grade 1 or 2 palpable indurations due to
surgery were observed, most patients did not experience any
breast color change or palpable induration immediately after
S-PBI. Any minimal color change or palpable induration
had mostly recovered by the first follow-up visit after S-
PBI, similar to the WBI group. Breast skin thickness is
well known for its relationship with palpable induration, and
radiotherapy is a well-known cause of thickening (27). In
our study, the change in skin thickness after S-PBI appears
to be limited to the tumor bed, in contrast to the diffuse
skin thickening observed after WBI. These favorable toxicity
profiles are comparable to those of the UTSW’s identical dose
cohort (10). They are also remarkably more favorable than
those observed in prospective 3D-CRT A-PBI trials (6, 28,
29). In contrast to widespread concerns about hypofractionated
radiotherapy in South Korea, S-PBI proved to be safe in
terms of early toxicities in Korean women, despite small
breast volumes.
Despite these promising findings, the KNHI reimbursement
system still acts as a major barrier to S-PBI. The unreasonably
low total income from S-PBI compared to WBI would ultimately
prevent adoption of any form of A-PBI in Korean hospitals,
even with sufficient proof of the technical feasibility and safety
of S-PBI. Given the rapid developments in high-precision
radiotherapy, the reimbursement system based on fraction size as
a new parameter is a solution that should be actively considered
(30). This could motivate hospitals to reduce loadings for
patients, and ultimately provoke widespread use of A-PBI in
Korean women.
Limitations of our study are its retrospective, single-
institution nature, the limited number of patients, and the
relatively short follow-up period. Longer follow-up may reveal
whether these promising dosimetric outcomes andminimal early
toxicity would translate into rare late toxicities and excellent
cosmesis. However, we firmly believe that our first experience of
S-PBI in Korean women will act as a cornerstone for widespread
use of A-PBI in this population.
In conclusion, the first experience of S-PBI in Korean women
demonstrated that it is a feasible and safe treatment for low-
risk early breast cancer patients. Despite smaller breast volumes,
outstanding dosimetric outcomes and successful fiducial tracking
were achieved, with rare early toxicities. Based on this first
experience in South Korea, we have initiated a prospective study
(NCT03568981) to test S-PBI in terms of cosmesis and quality of
life compared to WBI in early breast cancer.
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